A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
about
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase Ib trial of continuous ...... prior erlotinib or gefitinib.
@en
type
label
A phase Ib trial of continuous ...... prior erlotinib or gefitinib.
@en
prefLabel
A phase Ib trial of continuous ...... prior erlotinib or gefitinib.
@en
P2093
P1433
P1476
A phase Ib trial of continuous ...... g prior erlotinib or gefitinib
@en
P2093
Amelia Insa
David Schnell
Dolores Isla
Enric Carcereny Costa
Margarita Majem
Marta Puig
Noemí Reguart
Rafael Rosell
Ramón Palmero
P304
P356
10.1016/J.LUNGCAN.2017.03.009
P577
2017-03-22T00:00:00Z